Trade Biogen Inc. - BIIB CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.43
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 235.17
• Open: 233.08
• 1-Year Change: 62.55%
• Day's Range: 231.76 - 236.02

Trade Biogen Inc. - BIIB

Biogen Inc. (BIIB) is a biotechnology company in the field of neurological and neurodegenerative diseases. 

Established in 1978 and headquartered in Cambridge, Massachusetts, Biogen has devoted its scientific research to defeating neurological diseases, like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). 

With the aid of some of the world’s leading neuroscientists and neurologists, Biogen has sought treatments against common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP). 

The use of advanced technologies and engineering skills has enabled Biogen to bring effective medicines to the market. The company’s products include SPINRAZA for the treatment of SMA; TECFIDERA, AVONEX, FAMPYRA, VUMERITY and TYSABRI for multiple sclerosis; ADUHELM for Alzheimer’s disease; and FUMADERM for the treatment of severe plaque psoriasis.

Biogen has made an agreement with Genentech, a member of the Roche Group for business and financial rights, with respect to RITUXAN, GAZYVA and OCREVUS. It’s constantly looking at ways to improve its research and development to compete against other biotech giants like Pfizer Inc (PFE), Johnson & Johnson (JNJ) and Amgen (AMGN). 

Biogen went public in September 1991. It trades on the Nasqaq under the ticker ‘BIIB’.